Faron Pharmaceuticals Oy (FARON.HE) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · Finland
Faron Pharmaceuticals Oy financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 0.00 EUR | 0.00 EUR |
| Operating income | -18.67 m EUR | -18.96 m EUR |
| EBIT | -21.97 m EUR | -25.99 m EUR |
| Net income | -25.92 m EUR | -27.26 m EUR |
| Diluted EPS – continuing operations | -0.23 EUR | -0.22 EUR |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, the company develops receptors involved in regulation of immune response in organ damage and bone marrow regeneration. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
More stocks
- NTF Intergroup (Thailand) Public Company Limited (NTF.BK)
- Mediaco Holding Inc. (MDIA)
- First Bankers Trustshares Inc (FBTT)
- Vittia Fertilizantes (VITT3.SA)
- iBio, Inc. (IBIO)
- Mars Semiconductor Corp. (6708.TWO)
- Hwaseung Corporation Co Ltd (013520.KS)
- Tenaya Therapeutics, Inc. (TNYA)
- LapWall Oyj (LAPWALL.HE)
- Sempio Foods Co (248170.KS)
- IEVA GROUP S.A. (ALIEV.PA)
- Baikowski SASU (ALBKK.PA)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.